Two Alzheimer’s Organizations to Fund Phase 2 Trial of Amylyx Combo Therapy
The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation will fund a Phase 2 clinical trial of a combination therapy that Amylyx Pharmaceuticals is developing for Alzheimer’s disease. Amylyx will receive $1.85 million for the trial of AMX0035, which consists of an oral formulation of sodium phenylbutyrate (PB) and tauroursodeoxycholic-acid…